Albendazole.

ApprovedSmall molecule

GSK

Albendazole. is one of 234 small molecule programs targeting Malnutrition. It is currently in Approved.

Indications

Total Trials

Active Trials

233

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalnutritionActive, not recruiting

CysticercosisActive, not recruiting

OnchocerciasisActive, not recruiting

MortalityActive, not recruiting

MalariaActive, not recruiting

CognitionActive, not recruiting

Parasitic InfectionActive, not recruiting

Iron Deficiency AnemiaActive, not recruiting

StrongyloidiasisActive, not recruiting

Diarrheal DiseaseActive, not recruiting

MalnutritionPreclinical

Active, not recruiting

CysticercosisPreclinical

Active, not recruiting

OnchocerciasisPhase 3

Active, not recruiting

MortalityPhase 3

Active, not recruiting

MalariaPhase 2/Phase 3

Active, not recruiting

CognitionPreclinical

Active, not recruiting

Parasitic InfectionApproved

Active, not recruiting

Iron Deficiency AnemiaApproved

Active, not recruiting

StrongyloidiasisPhase 3

Active, not recruiting

Diarrheal DiseaseApproved

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

Albendazole.

GSK

Approved

3 2

Biltricide

Bayer

Preclinical

1 3

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

1 6

IV LBH589

Novartis

Preclinical

1 7

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 8

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 9

RTS,S/AS01E

GSK

Preclinical

4 10

Piperaquine

UUniversity of Oxford

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Treatment

NCT03435718

N/AActive, not recruiting

Cognition

NCT05949190

Post-ApprovalNot yet recruiting

Cysticercosis

NCT06376396

Post-ApprovalRecruiting

Treatment

NCT07074444

Clinical

Trials by Indication[1]

Treatment8 trials

Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults

Not yet recruiting·OOxfendazole Development Group·Phase 2·NCT03435718·250 enrolled

Impact of Alternative Treatment Strategies and Delivery Systems for Soil-transmitted Helminths in Kenya

Completed·LLondon School of Hygiene and Tropical Medicine·Phase 4·NCT02397772·21,761 enrolled

Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation

Completed·UUniversity of Washington·N/A·NCT00130910·234 enrolled

Show 5 more trials

Relative Efficacy of Two Regimens of Ante-helminthic Treatment

Completed·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·N/A·NCT00367627·200 enrolled

Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel

Recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 4·NCT07074444·318 enrolled

Treatment of Asymptomatic Toxocariasis With Albendazole in Children

Unknown status·—·Phase 3·NCT00755560·45 enrolled

Intestinal Microbiome Post-Azythromycin/Albendazole Treatment

Withdrawn·UUniversity of California, San Francisco·Phase 4·NCT03032042

Study of the Efficacy of Oxfendazole Compared to Albendazole in the Treatment of Trichuris Trichiura Infection in Adults

Withdrawn·JJohns Hopkins Bloomberg School of Public Health·Phase 2·NCT02636803

Cysticercosis6 trials

RCT ALB for SA Cysticercosis

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00133458

A Pilot Study of Neurocysticercosis Treatment

Completed·—·Phase 3·NCT00283699·178 enrolled

Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)

Completed·UUniversidad Peruana Cayetano Heredia·Phase 2/3·NCT00441285·156 enrolled

Show 3 more trials

Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis

Not yet recruiting·RR-Evolution Worldwide S.r.l. Impresa Sociale·Phase 4·NCT06376396·300 enrolled

Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00290823·110 enrolled

Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis

Completed·JJohns Hopkins University·N/A·NCT00004403·120 enrolled

Children4 trials

Albendazole Dose Finding and Pharmacokinetics in Children and Adults

Completed·JJennifer Keiser·Phase 2·NCT03527745·700 enrolled

Deworming and Enhanced Vitamin A Every 6 Month in Rural Indian Children Aged 1-6

Completed·UUniversity of Oxford·Phase 4·NCT00222547·720,000 enrolled

Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren

Completed·UUniversiteit Antwerpen·Phase 3·NCT01722539·616 enrolled

Show 1 more trial

Effect of Routine Deworming on Weight of Children

Completed·—·N/A·NCT03155035·300 enrolled

Malnutrition4 trials

Nutritional and Anti-infective Interventions for Malnutrition in Pregnancy (Beleuman Welbodi)

Completed·WWashington University School of Medicine·N/A·NCT03079388·1,489 enrolled

Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition

Withdrawn·WWashington University School of Medicine·N/A·NCT01395381

Package of Interventions After Recovering From Moderate Acute Malnutrition

Completed·WWashington University School of Medicine·N/A·NCT02351687·1,499 enrolled

Show 1 more trial

Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old

Completed·IInstitut Pasteur·Phase 3·NCT03474276·1,357 enrolled

Malaria3 trials

Impact of Repeated Anthelmintic Treatment on the Risk of Malaria in Kenyan School Children

Completed·LLondon School of Hygiene and Tropical Medicine·N/A·NCT01658774·2,377 enrolled

Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study

Completed·—·Phase 2/3·NCT02509481·2,712 enrolled

Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children

Unknown status·LLondon School of Hygiene and Tropical Medicine·N/A·NCT05354258·600 enrolled

34 more indications

Lymphatic Filariasis3 trials

Effect of Albendazole Dose on Treatment of Lymphatic Filariasis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00511004·40 enrolled

Lymphatic Filariasis (LF) in Ivory Coast

Completed·UUniversity Hospitals Cleveland Medical Center·N/A·NCT02974049·189 enrolled

Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis

Withdrawn·EEmory University·Phase 4·NCT01903057

Excretion2 trials

Serum Pharmacokinetic Disposition and Urinary Excretion of Albendazole

Completed·UUniversidad Nacional de Salta·Phase 1·NCT03192449·8 enrolled

Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva

Unknown status·UUniversidad Nacional de Salta·N/A·NCT05453045·12 enrolled

Effectiveness2 trials

Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms

Terminated·BBarcelona Institute for Global Health·Phase 2/3·NCT05124691·1,001 enrolled

Effectiveness of High-dose Zinc Therapy and Albendazole in the Treatment of Environmental Enteropathy

Completed·WWashington University School of Medicine·N/A·NCT01440608·225 enrolled

Efficacy2 trials

Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora

Completed·—·Phase 4·NCT01192802·200 enrolled

Efficacy Albendazole and Levamisole Against STH on Unguja

Completed·NNatural History Museum, United Kingdom·Phase 4·NCT00659997·20 enrolled

Onchocerciasis2 trials

IVM Alone vs ALB + IVM Against Onchocerciasis

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 3·NCT03238131·272 enrolled

Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

Completed·MMedicines Development for Global Health·Phase 3·NCT04311671·12,979 enrolled

Safety and Efficacy2 trials

A Safety and Efficacy Study of Different Doses of Oxfendazole Compared to a Single Dose of Albendazole to Treat Trichuris Trichiura Infection in Adults

Recruiting·AAsociacion Benefica Prisma·Phase 2·NCT04713787·249 enrolled

Safety and Efficacy of Drug Combinations Against Trichuris Trichiura

Completed·DDBL -Institute for Health Research and Development·N/A·NCT01050452·750 enrolled

Mortality1 trial

Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy

Completed·AAnna Griffiths, MRC·Phase 3·NCT01825031·1,805 enrolled

Iron deficiency anemia1 trial

Daily Versus Alternate Day Regimen of Iron Supplementation in Children with Iron Deficiency Anemia

Active, not recruiting·—·Phase 4·NCT06631612·72 enrolled

Tuberculosis1 trial

Deworming Against Tuberculosis

Completed·LLinkoeping University·N/A·NCT00857116·140 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of IVM/ALB Co-administration

Completed·JJennifer Keiser·Phase 2/3·NCT03527732·1,673 enrolled

Hookworm Infection1 trial

Triple Combinations Against Hookworm Infections in Lao

Completed·SSwiss Tropical & Public Health Institute·Phase 4·NCT03278431·420 enrolled

Double-blind1 trial

A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis

Completed· GSK logo

GSK·Phase 3·NCT00002191

Diarrheal Disease1 trial

The Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in Vietnamese School Children

Withdrawn·OOxford University Clinical Research Unit, Vietnam·Phase 4·NCT02597556

Pediatric Patients1 trial

Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients

Completed·AAlejandro Krolewiecki·Phase 2·NCT04041453·176 enrolled

Drug Therapy1 trial

Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 2·NCT01975441·182 enrolled

Growth1 trial

Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth

Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT01748929·1,010 enrolled

Infections1 trial

A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children

Completed·UUniversity Ghent·Phase 4·NCT01087099·1,750 enrolled

Clinical Trial1 trial

SANCC: Clinical Trial Early Intervention

Withdrawn·OOregon Health and Science University·Phase 2·NCT03950037

Eosinophilia1 trial

Specific Versus Empirical Anthelminthic Treatment in Eosinophilia

Recruiting·PPrince of Songkla University·N/A·NCT06265870·700 enrolled

CLE1 trial

Effect of Albendazole Dose on Clearance of Filarial Worms

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00339417·1,000 enrolled

Age1 trial

Combined Package of Interventions for Environmental Enteropathy

Completed·WWashington University School of Medicine·N/A·NCT02253095·253 enrolled

ISS1 trial

Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)

Completed·UUniversity of Washington·Phase 3·NCT03014167·357,716 enrolled

Chemotherapy1 trial

Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection

Completed·IIndian Council of Medical Research·Phase 4·NCT02005653·146 enrolled

Hemoglobin1 trial

Impact of Periodontal Treatment on Serum Levels of Hepcidin and Hemoglobin

Completed·—·Phase 4·NCT02641210·63 enrolled

Disease Progression1 trial

Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression

Completed·UUniversity of Washington·N/A·NCT00507221·948 enrolled

Adjuvant1 trial

The Role of Adjuvant Albendazole After Pulmonary Hydatid Cyst Resection

Unknown status·—·N/A·NCT06483880·24 enrolled

Parasitic Infection1 trial

Parasitic Infection in Anemic Pregnant Women

Unknown status·—·Phase 4·NCT04391998·200 enrolled

Strongyloidiasis1 trial

Ivermectin Versus Albendazole for Chronic Strongyloidiasis

Completed·MMahidol University·Phase 3·NCT00765024·90 enrolled

MPR1 trial

Does Treating Hookworm Improve Productivity of Small Subsistence Farmers

Unknown status·—·N/A·NCT02102321·300 enrolled

Infection1 trial

Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

Completed·—·Phase 2·NCT03172975·39 enrolled

Adverse Events1 trial

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection

Terminated· AbbVie logo

AbbVie·Phase 2·NCT04913610·153 enrolled

Cognition1 trial

Improving Cognition and Gestational Duration With Targeted Nutrition

Active, not recruiting·WWashington University School of Medicine·N/A·NCT05949190·1,660 enrolled

Azithromycin1 trial

PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )

Completed·LLihir Medical Centre·Phase 2·NCT03664063·42 enrolled

Unspecified3 trials

Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population

Completed· GSK logo

GSK·Phase 1·NCT01755637·56 enrolled

Design and Clinical Evaluation of a School Meal With Deworming Properties

Completed·KKenya Medical Research Institute·Phase 2/3·NCT02725255·326 enrolled

Moxidectin for LF, Cote d'Ivoire (DOLF)

Completed·WWashington University School of Medicine·Phase 3·NCT04410406·164 enrolled

Sources

References

[1]
ClinicalTrials.gov — 68 trial records for Albendazole.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Albendazole. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Albendazole.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GSK

Albendazole.

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Treatment8 trials

Cysticercosis6 trials

Children4 trials

Malnutrition4 trials

Malaria3 trials

Lymphatic Filariasis3 trials

Excretion2 trials

Effectiveness2 trials

Efficacy2 trials

Onchocerciasis2 trials

Safety and Efficacy2 trials

Mortality1 trial

Iron deficiency anemia1 trial

Tuberculosis1 trial

Efficacy and Safety1 trial

Hookworm Infection1 trial

Double-blind1 trial

Diarrheal Disease1 trial

Pediatric Patients1 trial

Drug Therapy1 trial

Growth1 trial

Infections1 trial

Clinical Trial1 trial

Eosinophilia1 trial

CLE1 trial

Age1 trial

ISS1 trial

Chemotherapy1 trial

Hemoglobin1 trial

Disease Progression1 trial

Adjuvant1 trial

Parasitic Infection1 trial

Strongyloidiasis1 trial

MPR1 trial

Infection1 trial

Adverse Events1 trial

Cognition1 trial

Azithromycin1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News